1. A clinician must choose a single benzimidazole that will both clear a patient's luminal intestinal nematodes AND act on a coexisting tissue-invasive larval cestode focus. Integrating the shared mechanism of the benzimidazole class with their differing pharmacokinetics, which choice and reasoning is correct?
A) Either benzimidazole is equivalent, because a shared tubulin-binding mechanism guarantees identical tissue and luminal efficacy regardless of absorption
B) Albendazole, because although both benzimidazoles share the same tubulin-binding mechanism, only albendazole is absorbed well enough (further enhanced by a fatty meal) to reach the systemic and tissue concentrations a larval cestode focus requires, while still clearing luminal nematodes
C) Mebendazole, because its very poor absorption concentrates it in tissue compartments where larval cysts reside
D) Neither benzimidazole can serve, so praziquantel must replace both for the luminal and the tissue targets simultaneously
E) Mebendazole, because tubulin binding is irrelevant in tissue and only luminal contact matters for cestode larvae
ANSWER: B
Rationale:
The two benzimidazoles share the same molecular mechanism (binding parasite beta-tubulin to block microtubule assembly), so the deciding factor for a tissue target is pharmacokinetic, not mechanistic. Albendazole is absorbed appreciably, and its absorption is enhanced by a fatty meal because it is lipophilic, allowing it to reach the systemic and tissue concentrations a larval cestode focus requires while still acting on luminal nematodes. This integrates the class mechanism with the absorption distinction.
Option A: Option A is incorrect; a shared mechanism does not guarantee identical efficacy when tissue penetration differs, which is the entire point.
Option C: Option C is incorrect; mebendazole's poor absorption keeps it in the gut lumen, not in tissue.
Option D: Option D is incorrect; albendazole can serve both roles, and praziquantel is not the agent for luminal nematodes or for larval cestode tissue cysts.
Option E: Option E is incorrect; tubulin binding is the very mechanism of action and is not irrelevant in tissue.
2. A patient with neurocysticercosis is also receiving a corticosteroid (standard in neurocysticercosis) and, separately, rifampicin for tuberculosis. The team is considering praziquantel. Integrating praziquantel's CYP3A4-dependent metabolism with both co-medications, which conclusion is best supported?
A) Both co-medications raise praziquantel exposure, so the praziquantel dose should be reduced to avoid toxicity
B) The corticosteroid raises central praziquantel levels while rifampicin lowers systemic levels, so the two cancel out and no adjustment is needed
C) Only rifampicin matters; corticosteroids have no effect on praziquantel disposition in any compartment
D) Rifampicin inhibits CYP3A4 and the corticosteroid induces it, so praziquantel accumulates dangerously
E) Both co-medications act against praziquantel efficacy — rifampicin induces CYP3A4 and sharply lowers systemic praziquantel levels, and the corticosteroid lowers praziquantel cerebrospinal fluid concentrations — so praziquantel is a poor central choice here, favoring an albendazole-based approach
ANSWER: E
Rationale:
Two independent effects both reduce praziquantel's usefulness in this patient. Rifampicin is a potent CYP3A4 inducer that sharply lowers systemic praziquantel concentrations, and the corticosteroid lowers praziquantel cerebrospinal fluid levels; since albendazole's central penetration is not meaningfully reduced by corticosteroids and it is not subject to the same rifampicin-driven loss of central efficacy in this role, an albendazole-based approach is favored. This integrates the CYP3A4 fact with both co-medication effects.
Option A: Option A is incorrect; neither co-medication raises praziquantel exposure.
Option B: Option B is incorrect; the corticosteroid lowers, not raises, central praziquantel levels, so there is no cancellation.
Option C: Option C is incorrect; the corticosteroid does affect praziquantel central concentrations.
Option D: Option D inverts the pharmacology: rifampicin induces rather than inhibits CYP3A4, and the corticosteroid does not induce it to cause accumulation.
3. You know that pyrantel causes depolarizing spastic paralysis (a nicotinic acetylcholine receptor agonist) and that ivermectin causes hyperpolarizing flaccid paralysis (opening glutamate-gated chloride channels). A researcher proposes co-administering pyrantel and ivermectin to a nematode, expecting additive killing. Applying the electrophysiologic principle to this novel pairing, which prediction is most defensible?
A) The two will be reliably synergistic because both act on worm neuromuscular signaling, so simultaneous use always multiplies effect
B) The two cannot interact at all because they act on completely separate organ systems within the worm
C) Because one drug depolarizes the muscle toward spastic paralysis while the other hyperpolarizes it toward flaccid paralysis, their opposing effects on membrane potential may counteract rather than reinforce each other, so additive killing should not be assumed and antagonism is plausible
D) Ivermectin will convert pyrantel into a stronger depolarizing agonist, guaranteeing enhanced spastic paralysis
E) The combination will produce pure flaccid paralysis with no contribution from pyrantel under any circumstances
ANSWER: C
Rationale:
The governing principle is the direction of the membrane-potential change. Pyrantel drives depolarization (spastic paralysis), while ivermectin drives hyperpolarization (flaccid paralysis); pushing the muscle membrane in opposite directions can counteract rather than reinforce the paralytic effect, so additive killing cannot be assumed and antagonism is a plausible outcome. This applies the spastic-versus-flaccid principle to a new drug pair.
Option A: Option A is incorrect; acting on the same system does not guarantee synergy when the effects oppose.
Option B: Option B is incorrect; both drugs act on the worm neuromuscular membrane, so interaction is possible.
Option D: Option D is incorrect; ivermectin does not transform pyrantel into a stronger agonist.
Option E: Option E is incorrect; the outcome is not a guaranteed pure flaccid paralysis, since pyrantel's depolarizing action still contributes and may oppose ivermectin.
4. Onchocerciasis control relies on repeated annual (or semi-annual) ivermectin rather than a single curative course. Integrating ivermectin's predominantly microfilaricidal action with the biology of the adult Onchocerca worm, which explanation best accounts for this program design?
A) Ivermectin chiefly kills the microfilariae and only weakly affects the long-lived adult worms, which continue producing new microfilariae; repeated dosing is therefore needed to keep microfilarial loads (and thus transmission and skin/eye disease) suppressed across the adult worms' reproductive lifespan
B) Ivermectin rapidly sterilizes and kills adult worms in a single dose, so annual dosing is purely a bureaucratic formality
C) Ivermectin is macrofilaricidal but not microfilaricidal, so repeat dosing targets microfilariae the first dose could not reach
D) Repeat dosing is required only because ivermectin is extensively first-pass metabolized and a single dose never reaches the skin
E) Annual dosing exists solely to overcome universal high-grade ivermectin resistance present in all Onchocerca populations
ANSWER: A
Rationale:
Ivermectin is predominantly microfilaricidal and only weakly affects the long-lived adult Onchocerca worms, which keep producing microfilariae. Because the adults survive and continue reproducing, microfilarial loads rebound between treatments; repeated annual or semi-annual dosing is therefore needed to keep microfilarial density (and the transmission and skin/eye pathology it drives) suppressed across the adult worms' reproductive lifespan. This integrates the microfilaricidal-versus-macrofilaricidal distinction with parasite biology.
Option B: Option B is incorrect; ivermectin does not kill adult worms in a single dose.
Option C: Option C inverts the pharmacology; ivermectin is microfilaricidal, not macrofilaricidal.
Option D: Option D is incorrect; the program design reflects adult-worm survival and microfilarial rebound, not a claim that a single dose never reaches the skin.
Option E: Option E is incorrect; while reduced susceptibility has emerged in some foci, universal high-grade resistance across all populations is not the reason for routine repeat dosing.
5. A patient has multiple viable parenchymal neurocysticercosis cysts on imaging. Integrating three principles — antiparasitics act only on living cysts, dying cysts incite a dangerous inflammatory reaction, and corticosteroids reduce praziquantel central levels but not albendazole's — which overall management plan is internally consistent?
A) Withhold antiparasitic therapy because all neurocysticercosis cysts, viable or not, gain no benefit from treatment
B) Treat with praziquantel alone and withhold corticosteroids to preserve praziquantel cerebrospinal fluid levels
C) Treat with antiparasitic therapy but omit any corticosteroid, since inflammation around dying cysts is harmless
D) Treat the viable cysts with an albendazole-based antiparasitic regimen, give a corticosteroid concurrently to control the inflammatory reaction to dying cysts, and rely on albendazole because its central penetration is preserved despite the steroid
E) Treat only after the cysts calcify, since calcified cysts respond best to antiparasitics
ANSWER: D
Rationale:
A consistent plan integrates all three principles: viable cysts do benefit from antiparasitic therapy; killing them provokes inflammation that mandates a concurrent corticosteroid; and because the steroid lowers praziquantel central levels while sparing albendazole's, an albendazole-based regimen maintains effective central exposure.
Option A: Option A is incorrect; viable cysts do benefit, even though calcified-only cysts do not.
Option B: Option B is incorrect; omitting the corticosteroid is unsafe when viable cysts are being killed, and praziquantel alone is the wrong central choice here.
Option C: Option C is incorrect; inflammation around dying cysts is not harmless, which is exactly why a steroid is required.
Option E: Option E is incorrect; calcified cysts are dead and do not respond to antiparasitics, so waiting for calcification is wrong.
6. For cystic echinococcosis treated with PAIR (puncture-aspiration-injection-reaspiration) or surgery, albendazole is started before the procedure and continued afterward. Integrating the risk of intraoperative cyst-content spillage with the goal of preventing secondary disease, which rationale for this timing is correct?
A) Albendazole is begun before the procedure only to treat anticipated postoperative nausea and has no antiparasitic purpose
B) Spilled protoscoleces can seed new cysts, so albendazole is given before the procedure (to establish antiparasitic cover in advance) and continued afterward to reduce the chance that any protoscoleces released during the procedure establish secondary cysts
C) Pre-procedure albendazole physically hardens the cyst wall so that it cannot rupture during manipulation
D) Albendazole is started before the procedure to fully sterilize the cyst so the procedure itself becomes unnecessary in all cases
E) Post-procedure albendazole is unnecessary because spillage cannot occur once a cyst has been aspirated
ANSWER: B
Rationale:
The integrated rationale combines the seeding risk with prophylactic timing. Protoscoleces spilled during puncture or surgery can establish new (secondary) cysts; starting albendazole beforehand establishes antiparasitic cover in advance, and continuing it afterward reduces the chance that any released protoscoleces take hold.
Option A: Option A is incorrect; the purpose is antiparasitic cover against seeding, not nausea control.
Option C: Option C is incorrect; albendazole does not physically harden or seal the cyst wall.
Option D: Option D is incorrect; for active cysts the drug complements rather than replaces the procedure, so it does not make the procedure unnecessary in all cases.
Option E: Option E is incorrect; spillage of viable protoscoleces can occur during the procedure, which is precisely why post-procedure cover matters.
7. A nematode population has developed high-level benzimidazole resistance through a beta-tubulin codon-200 substitution. A program considers switching to ivermectin. Integrating the mechanism of benzimidazole resistance with ivermectin's distinct target, what is the most defensible prediction about cross-resistance, and what caveat applies?
A) Benzimidazole resistance automatically confers ivermectin resistance because all antihelminthic resistance shares a single common pathway
B) Ivermectin will certainly fail, because a beta-tubulin mutation also disables glutamate-gated chloride channels
C) The two drugs share the same target, so switching is pointless
D) Benzimidazole resistance guarantees that ivermectin will be permanently curative with no monitoring needed
E) Because benzimidazole resistance arises at beta-tubulin while ivermectin acts at glutamate-gated chloride channels, a target-specific beta-tubulin mutation should not by itself confer ivermectin resistance, so switching is rational — but ivermectin has its own independent resistance mechanisms (chloride-channel mutations, efflux-pump upregulation), so efficacy monitoring is still required
ANSWER: E
Rationale:
Resistance that is specific to one drug's target does not automatically extend to a drug acting at a different target. A beta-tubulin codon-200 mutation impairs benzimidazole binding but does not affect glutamate-gated chloride channels, so it should not by itself confer ivermectin resistance, making the switch rational. The necessary caveat is that ivermectin has its own independent resistance mechanisms (chloride-channel subunit mutations and efflux-pump upregulation), so continued efficacy monitoring is still required. This integrates target-based reasoning with resistance biology.
Option A: Option A is incorrect; there is no single common resistance pathway shared by all antihelminthics.
Option B: Option B is incorrect; a beta-tubulin mutation does not disable chloride channels.
Option C: Option C is incorrect; the two drugs act at different targets, so switching is not pointless.
Option D: Option D is incorrect; it ignores ivermectin's own resistance mechanisms and the resulting need for monitoring.
8. A patient from a Strongyloides-endemic region has unexplained peripheral eosinophilia and is scheduled to begin high-dose corticosteroids and additional immunosuppression. Integrating the cause of eosinophilia, the danger of immunosuppression in latent strongyloidiasis, and the first-line agent for Strongyloides, which pre-treatment strategy is most coherent?
A) Proceed directly to immunosuppression, since eosinophilia in this context never reflects a treatable parasite
B) Begin immunosuppression first and treat the parasite reactively only if hyperinfection develops
C) Recognize that tissue-invasive helminths drive eosinophilia and that immunosuppression can convert latent strongyloidiasis into a frequently fatal hyperinfection, so test for Strongyloides and treat empirically with ivermectin (the first-line agent) before starting corticosteroids
D) Treat empirically with mebendazole before immunosuppression, since benzimidazoles are the definitive agent for Strongyloides
E) Treat empirically with praziquantel before immunosuppression, since Strongyloides is a fluke
ANSWER: C
Rationale:
A coherent strategy integrates three facts. Tissue-invasive helminths drive eosinophilia through an interleukin-5-mediated response, so unexplained eosinophilia in an at-risk patient warrants helminth evaluation; immunosuppression can convert latent strongyloidiasis into a frequently fatal hyperinfection; and ivermectin is the first-line agent for Strongyloides. The safe approach is therefore to test and treat (empirically with ivermectin) before starting corticosteroids.
Option A: Option A is incorrect; such eosinophilia can absolutely reflect a treatable parasite.
Option B: Option B is incorrect; waiting for hyperinfection to declare itself risks a fatal outcome.
Option D: Option D is incorrect; benzimidazole efficacy against Strongyloides is inferior, so mebendazole is not the definitive agent.
Option E: Option E is incorrect; Strongyloides is a nematode, not a fluke, and praziquantel does not treat it.
9. A patient is found to harbor three concurrent infections: an intestinal roundworm (hookworm), a blood fluke (Schistosoma), and an intestinal tapeworm (Taenia saginata). Integrating drug selection by helminth class, which combined plan correctly matches each parasite to an appropriate agent?
A) Albendazole for the hookworm (nematode), praziquantel for the schistosome (trematode), and praziquantel for the intestinal tapeworm (cestode), recognizing praziquantel covers both the blood fluke and the luminal tapeworm while the benzimidazole handles the roundworm
B) Praziquantel for all three, since a single agent covers nematodes, trematodes, and cestodes equally
C) Albendazole for all three, since benzimidazoles cover roundworms, flukes, and tapeworms equally
D) Diethylcarbamazine for the hookworm, triclabendazole for the schistosome, and ivermectin for the tapeworm
E) Ivermectin for all three, since chloride-channel activation is universal across helminth classes
ANSWER: A
Rationale:
Correct selection follows helminth class. The hookworm (a nematode) is treated with a benzimidazole such as albendazole; the schistosome (a trematode) is treated with praziquantel; and the intestinal Taenia saginata (an adult luminal cestode) is also treated with praziquantel. Thus praziquantel covers both the blood fluke and the luminal tapeworm, while the benzimidazole handles the roundworm.
Option B: Option B is incorrect; praziquantel does not reliably treat intestinal roundworms such as hookworm.
Option C: Option C is incorrect; benzimidazoles are not the agents of choice for blood flukes or for adult luminal tapeworms.
Option D: Option D is incorrect; it misassigns a filarial agent (diethylcarbamazine) to a hookworm, the Fasciola agent (triclabendazole) to a schistosome, and a chloride-channel agent (ivermectin) to a tapeworm.
Option E: Option E is incorrect; ivermectin does not cover all three classes, and chloride-channel activity is not a universal antihelminthic solution.
10. A pregnant patient in the second trimester has both a significant soil-transmitted nematode burden and confirmed schistosomiasis. Integrating the pregnancy-safety profiles of the relevant agents, which plan is most appropriate?
A) Use diethylcarbamazine for both infections, as it is the preferred antihelminthic in pregnancy
B) Use ivermectin as the routine first choice for both infections in any pregnancy
C) Defer all treatment until after delivery, since every antihelminthic is absolutely contraindicated throughout pregnancy
D) Use a single-dose benzimidazole (albendazole or mebendazole), which is used from the second trimester onward for soil-transmitted helminthiasis, together with praziquantel for the schistosomiasis, as praziquantel is considered acceptable in pregnancy
E) Use triclabendazole for the nematodes and withhold treatment for the schistosomiasis until postpartum
ANSWER: D
Rationale:
Integrating the agents' pregnancy profiles gives a clear plan: a single-dose benzimidazole (albendazole or mebendazole) is used for soil-transmitted helminthiasis from the second trimester onward, and praziquantel is considered acceptable in pregnancy for schistosomiasis, so both infections can be addressed.
Option A: Option A is incorrect; diethylcarbamazine is contraindicated in pregnancy and is a filarial agent, not a treatment for soil-transmitted nematodes or schistosomes.
Option B: Option B is incorrect; ivermectin has limited pregnancy safety data and is generally avoided except in life-threatening disease, so it is not a routine first choice.
Option C: Option C is incorrect; treating a significant burden from the second trimester is a net benefit, so blanket deferral is wrong.
Option E: Option E is incorrect; triclabendazole is the Fasciola agent, not a soil-transmitted nematode treatment, and praziquantel can be used in pregnancy rather than deferred.
11. Praziquantel's common adverse effects (headache, dizziness, nausea, abdominal pain, malaise) are largely attributed to the death of parasites rather than to direct drug toxicity. Integrating this mechanism with parasite burden, which prediction about a patient with a very heavy worm burden is best supported?
A) A heavy worm burden predicts fewer symptoms, because more worms competitively absorb the drug and lower its effective concentration
B) Because much of the reaction reflects antigen release and inflammation from dying parasites, a patient with a very heavy worm burden may experience a more pronounced systemic reaction as a large parasite mass dies, so greater monitoring and supportive care may be warranted
C) Worm burden is irrelevant to symptom severity because the adverse effects are purely direct chemical toxicity of praziquantel
D) A heavy burden eliminates all adverse effects because the worms neutralize the drug before any reaction can occur
E) Symptoms occur only in patients with no worms at all, as a placebo phenomenon unrelated to parasite death
ANSWER: B
Rationale:
If much of praziquantel's adverse-effect profile derives from antigen release and inflammation as parasites die, then the size of the dying parasite mass should influence reaction severity. A patient with a very heavy worm burden may therefore have a more pronounced systemic reaction as a large mass of worms dies, justifying closer monitoring and supportive care. This integrates the worm-death-reaction mechanism with burden.
Option A: Option A is incorrect; a heavier burden predicts a larger, not smaller, death reaction.
Option C: Option C is incorrect; the effects are largely from parasite death, not purely direct chemical toxicity, so burden is relevant.
Option D: Option D is incorrect; worms do not neutralize the drug to abolish the reaction.
Option E: Option E is incorrect; the reaction is tied to parasite death, not a placebo phenomenon in worm-free patients.
12. Opisthorchis viverrini is a liver fluke endemic in parts of Southeast Asia. Integrating its chronic biliary infection with a recognized long-term oncologic consequence, which statement best justifies treating even relatively asymptomatic infections with praziquantel?
A) Chronic O. viverrini infection is harmless once asymptomatic, so treatment offers no benefit beyond reassurance
B) O. viverrini does not respond to praziquantel, so triclabendazole must be used as for Fasciola
C) The infection causes acute fulminant hepatitis within days, so treatment is purely an emergency measure with no chronic dimension
D) The only rationale for treatment is to reduce egg shedding into the environment; there is no individual health benefit
E) Chronic biliary infection with O. viverrini is a recognized risk factor for cholangiocarcinoma (bile-duct cancer), so treating the infection with praziquantel addresses a long-term malignancy risk, not merely current symptoms
ANSWER: E
Rationale:
Integrating the chronicity of O. viverrini biliary infection with its oncologic consequence explains why treatment matters even when symptoms are mild: chronic infection is a recognized risk factor for cholangiocarcinoma, so eradicating the fluke with praziquantel addresses a long-term cancer risk rather than only relieving current symptoms.
Option A: Option A is incorrect; asymptomatic chronic infection is not harmless given the malignancy association.
Option B: Option B is incorrect; O. viverrini responds to praziquantel, unlike Fasciola.
Option C: Option C is incorrect; the key concern is chronic injury and cancer risk, not acute fulminant hepatitis.
Option D: Option D is incorrect; there is a clear individual health benefit (reducing cholangiocarcinoma risk), not merely environmental egg reduction.
13. Mass drug administration delivers benzimidazoles, ivermectin, praziquantel, and diethylcarbamazine to hundreds of millions of people, and the sustainability of these programs depends on maintaining drug efficacy. Integrating the resistance biology of these agents with public-health surveillance, why does an individual clinician's reporting of an unexpected treatment failure matter at the program level?
A) Individual treatment failures are irrelevant to programs, since resistance is detectable only by laboratory genome sequencing and never by clinical outcome
B) Reporting matters only for benzimidazoles, because ivermectin and praziquantel cannot develop reduced susceptibility under any circumstances
C) Because reduced susceptibility (for example, suboptimal ivermectin responses in some onchocerciasis foci, or beta-tubulin-mediated benzimidazole resistance) can emerge under sustained drug pressure, individual reports of unexpected treatment failure feed surveillance systems that detect emerging resistance early and guide changes to regimens before programs fail
D) Reporting failures encourages programs to abandon mass treatment entirely at the first sign of any failure, which is the goal
E) Clinician reports are discouraged because they introduce noise; only cure-rate surveys conducted years apart have any value
ANSWER: C
Rationale:
Integrating resistance biology with surveillance explains the value of clinician reporting: because reduced susceptibility can emerge under sustained drug pressure (suboptimal ivermectin responses in some onchocerciasis foci, beta-tubulin-mediated benzimidazole resistance), individual reports of unexpected treatment failure contribute to surveillance systems that detect emerging resistance early and inform timely regimen changes before programs lose efficacy.
Option A: Option A is incorrect; clinical outcomes such as treatment failure are an important early signal, not irrelevant.
Option B: Option B is incorrect; reduced susceptibility is a concern for ivermectin as well, not benzimidazoles alone.
Option D: Option D is incorrect; the aim is early detection and adaptation, not wholesale abandonment of mass treatment at any failure.
Option E: Option E is incorrect; clinician reports complement, rather than detract from, periodic cure-rate surveys.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.